Our Science – Dubois Website
Sigrid P. Dubois, Ph.D.
The main focus of the laboratory of Dr. Thomas A. Waldmann is the role of Interleukin-2 (IL-2) and IL-15 on the regulation of human immune responses.
One of the Dr. Dubois' major contributions has been the characterization of the mechanism of action of IL-15. Instead of acting as a soluble factor, IL-15Ralpha retains IL-15 via a high-affinity interaction on the cell surface and trans-presents it to neighboring NK and CD8+ T cells that express IL-2/15Rbeta and gammac. Studies conducted by Dr. Dubois have helped in understanding the regulation of IL-15 production and its role in the development of some CD8 populations as well as its contribution to the activation/proliferation of NK cells. Dr. Dubois has been involved in the use of IL-15 in the treatment of malignancies in mice, where it has been found to be effective. Ultimately, the work of Dr. Dubois contributed to the GMP production of IL-15 that has been used in a first-in-human clinical trial as a new therapy for patients with metastatic malignant melanoma and renal cell cancer. Currently, two main projects conducted by Dr. Dubois focus on: 1) the role of IL-15 in the development of T cell malignancy, and
2) the development of a new therapy supporting the anti-tumor activity of NK cells.
This page was last updated on 5/29/2014.